UPDATE: Impax Laboratories (IPXL) Posts Q3 EPS of 48c; Sees Q4 Revs Down 15% - 20%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Impax Laboratories (IPXL) Story Intact Despite Bruising
October 31, 2012 2:13 PM EDTCanaccord Genuity reiterated a Buy rating on Impax Laboratories (NASDAQ: IPXL) but trimmed its price target to $27.00 (from $29.00). Yesterday Impax Laboratories reported Q3 earnings and revenue that fell short of expectations.
Commenting on the results, analyst Randall Stanicky said, "Expect disappointment... More
